Zobrazeno 1 - 10
of 368
pro vyhledávání: '"Paul Baas"'
Autor:
Jens Benn Sørensen, Paul Baas, Szimonetta Komjáthiné Szépligeti, Alma B. Pedersen, Søren P. Johnsen, Robert Carroll, Minouk J. Schoemaker, Caroline Rault, Melinda J. Daumont, Vera Ehrenstein
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor prognosis and limited treatment options. Immunotherapy shows potential for improved outcomes; however, real-world evidence on its use will take time to accumulat
Externí odkaz:
https://doaj.org/article/12feb6552e244e149a6d6c1e2c4ce6c3
Autor:
Mitesh J Borad, Giannoula Karagouga, Jun Yin, Stephen Murphy, Paul Baas, James Smadbeck, John Cheville, Alexa McCune, Aaron Mansfield, George Vasmatzis, Aakash P Desai, Farhad Kosari, Maria Disselhorst, Alireza Agahi, Tobias Peikert, Julia Udell, Sarah H Johnson, Janet Schaefer-Klein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation burden and no robust predictors of
Externí odkaz:
https://doaj.org/article/a6826c67289e41c885adfe1bf7000f0b
Autor:
Floris Dammeijer, Cornedine J. De Gooijer, Mandy van Gulijk, Melanie Lukkes, Larissa Klaase, Lysanne A. Lievense, Cynthia Waasdorp, Merel Jebbink, Gerben P. Bootsma, Jos A. Stigt, Bonne Biesma, Margaretha E.H. Kaijen-Lambers, Joanne Mankor, Heleen Vroman, Robin Cornelissen, Paul Baas, Vincent Van der Noort, Jacobus A. Burgers, Joachim G. Aerts
Publikováno v:
EBioMedicine, Vol 64, Iss , Pp 103160- (2021)
Background: Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, the randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significa
Externí odkaz:
https://doaj.org/article/3c5ff16d06e342ff8c1730cb7bdef69d
Autor:
Joanne M. Mankor, Maria J. Disselhorst, Myrthe Poncin, Paul Baas, Joachim G.J.V. Aerts, Heleen Vroman
Publikováno v:
EBioMedicine, Vol 62, Iss , Pp 103040- (2020)
Background: Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-1 monotherapy failed to provide benefit in phase
Externí odkaz:
https://doaj.org/article/ff10acfc49ea49d688bba34a12ea726f
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/0ec0dae6e8434cc6b37f8e3d5e4a91a0
Autor:
Zulfan Zazuli, Renate Kos, Joris D. Veltman, Wilma Uyterlinde, Cristina Longo, Paul Baas, Rosalinde Masereeuw, Susanne J. H. Vijverberg, Anke-Hilse Maitland-van der Zee
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
AimAntineoplastic effect of cisplatin, the first line treatment in non-small cell lung cancer (NSCLC), is hindered by its nephrotoxicity and myelotoxicity. Both low-dose and high-dose regimens are used in the management of NSCLC. The aim of this stud
Externí odkaz:
https://doaj.org/article/c730d5154a3f4bd197c342551827a6bb
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will high
Externí odkaz:
https://doaj.org/article/10c7079bacef4291a5eacb6277fba276
Autor:
Karlijn Hummelink, Mirte Muller, Theodora C. Linders, Vincent van der Noort, Petra M. Nederlof, Paul Baas, Sjaak Burgers, Egbert F. Smit, Gerrit A. Meijer, Michel M. van den Heuvel, Daan van den Broek, Kim Monkhorst
Publikováno v:
ERJ Open Research, Vol 5, Iss 1 (2019)
Objectives Molecular profiling of tumours has become the mainstay of diagnostics for metastasised solid malignancies and guides personalised treatment, especially in nonsmall cell lung cancer (NSCLC). In current practice, it is often challenging to o
Externí odkaz:
https://doaj.org/article/e4ad91cdd5f844d0b347201f793ab091
Autor:
Zulfan Zazuli, Susanne Vijverberg, Elise Slob, Geoffrey Liu, Bruce Carleton, Joris Veltman, Paul Baas, Rosalinde Masereeuw, Anke-Hilse Maitland-van der Zee
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Background: Nephrotoxicity is a notable adverse effect in cisplatin treated patients characterized by tubular injury and/or increased serum creatinine (SCr) with incidence varying from 20 to 70%. Pharmacogenomics has been shown to identify strongly p
Externí odkaz:
https://doaj.org/article/655455dad9484fa6afae16abeea18945
Autor:
Rianne de Vries, Niloufar Farzan, Timon Fabius, Frans H.C. De Jongh, Patrick M.C. Jak, Eric G. Haarman, Erik Snoey, Johannes C.C.M. In ’T Veen, Yennece W.F. Dagelet, Anke-Hilse Maitland-Van Der Zee, Annelies Lucas, Michel M. Van Den Heuvel, Marguerite Wolf-Lansdorf, Mirte Muller, Paul Baas, Peter J. Sterk
Publikováno v:
Chest.